Loading…
Cytosorbents Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -25.6% over 5Y.
today you would have $539.41▼ -46.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $12.78 | $0.91 | $1.11 | $1.55 | |
| P/S | 2.1x | 21.7x | 1.4x | 1.9x | 2.3x |
| P/B | 3.5x | 136.0x | 4.5x | 2.6x | 1.9x |
| EPS | -$0.13 | -$0.38 | -$0.65 | -$0.75 | |
| Profit margin | -76.15% | -22.12% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LFWDLifeward Ltd. | $7.46 | — | 3.3x | — | -225.65% | $21.13M |
| COCPCocrystal Pharma, Inc. | $1.10 | — | 14.5x | — | -311.68% | $21.19M |
| AKTXAkari Therapeutics Plc | $10.70 | — | 1.0x | — | -140.09% | $20.83M |
| LGVNLongeveron Inc. | $6.72 |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform in the United States, Germany, and internationally. Its flagship product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses, bilirubin in liver failure, myoglobin in trauma and critical illnesses, and inflammatory mediators and blood thinners in cardiac surgery applications, as well as to remove antithrombotic drugs and inflammatory mediators in cardiothoracic surgery applications. The company also develops DrugSorb-ATR antithrombotic removal system, an investigational device to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs; ECOS-300CY to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; and PuriFi, an advanced hemoperfusion pump for blood purification therapies. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Company description provided by Yahoo Finance.
| -58.21% |
| -94.09% |
| -111.76% |
| ROE | -131.72% | -138.88% | -186.54% | -124.55% | -92.76% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 20.5x |
| — |
| -203.61% |
| $21.42M |
| BNGOBionano Genomics, Inc. | $1.82 | — | 0.7x | — | -83.56% | $21.43M |
| CCMConcord Medical Services Holdings Ltd | $4.76 | — | — | — | -21.88% | $20.67M |